Skip to main content Accessibility help
×
Home

Reply to: Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?

  • J. Stone (a1), I. Koychev (a1) (a2), T. Reilly (a1) and P. McGuire (a1)
  • In response to commentaries on:

Copyright

Corresponding author

* Author for correspondence: J. Stone, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK. (Email: james.m.stone@kcl.ac.uk)

References

Hide All
Hallak, JE, Maia-de-Oliveira, JP, Abrao, J, Evora, PR, Zuardi, AW, Crippa, JA, Belmonte-de-Abreu, P, Baker, GB, Dursun, SM (2013). Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 70, 668676.
Hartz, SM, Pato, CN, Medeiros, H, Cavazos-Rehg, P, Sobell, JL, Knowles, JA, Bierut, LJ, Pato, MT; Genomic Psychiatry Cohort Consortium (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71, 248254.
Maia-de-Oliveira, JP, Baker, GB, Dursun, SM, Hallak, JE (2016). Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained? Psychological Medicine. Published online 9 December 2016. doi:10.1017/S003329171600307X.
Stone, JM, Morrison, PD, Koychev, I, Gao, F, Reilly, TJ, Kolanko, M, Mohammadinasab, A, Kapur, S, McGuire, PK (2016). The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychological Medicine 46, 34433450.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed